MedTrace Logo

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-16

No results posted yet for this study

Summary

This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.

Conditions

  • Chronic Pancreatitis
  • Mesenchymal Stem Cells

Interventions

BIOLOGICAL

Bone marrow-derived mesenchymal stem cells

MSC transplantation

OTHER

Placebo

Standard of Care

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Charlton Strange, M.D · Medical University of South Carolina

  • William Lancaster, M.D · Medical University of South Carolina

  • Hongjun Wang · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095532 on ClinicalTrials.gov